Alpha‐interferon therapy for chronic hepatitis B virus infection in children and Oriental patients

In summary, these four studies showed that alpha-IFN therapy alone produced sustained inhibition of HBV replication in a minority of Chinese adults with chronic HBV infection. The response was not improved by instituting treatment at an earlier age. The major reason for the poor response in Chinese patients is probably immune tolerance as a result of early exposure to HBV. The response in Chinese patients with elevated pre-treatment serum ALT levels, who presumably had ongoing endogenous immune lysis of infected hepatocytes, was significantly better than and comparable with that reported in Caucasian patients. Prednisone priming did not provide any additional advantage over therapy with IFN alone in patients with normal pre-treatment serum ALT levels, but appeared to have additional benefit in patients with elevated ALT levels.

[1]  A. Lok,et al.  Interferon alfa therapy in patients with chronic hepatitis B virus infection. Effects on hepatitis B virus DNA in the liver. , 1991, Gastroenterology.

[2]  A. Lok,et al.  Interferon antibodies may negate the antiviral effects of recombinant α‐interferon treatment in patients with chronic hepatitis B virus infection , 1990 .

[3]  A. Lok,et al.  Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infection. Incidence, predisposing factors and etiology. , 1990, Journal of hepatology.

[4]  H. Thomas,et al.  Which patients with chronic hepatitis B virus infection will respond to α‐interferon therapy? A statistical analysis of predictive factors , 1989, Hepatology.

[5]  A. Lok,et al.  Treatment of Chronic Hepatitis B with Interferon: Experience in Asian Patients , 1989, Seminars in liver disease.

[6]  R. Perrillo Treatment of Chronic Hepatitis B with Interferon: Experience in Western Countries , 1989, Seminars in liver disease.

[7]  Chien-Jen Chen,et al.  Factors affecting clearance of hepatitis B e antigen in hepatitis B surface antigen carrier children. , 1989, The Journal of pediatrics.

[8]  A. Lok,et al.  A longitudinal follow‐up of asymptomatic hepatitis B surface antigen‐positive chinese children , 1988, Hepatology.

[9]  A. Lok,et al.  LONG-TERM FOLLOW-UP IN A RANDOMISED CONTROLLED TRIAL OF RECOMBINANT α2-INTERFERON IN CHINESE PATIENTS WITH CHRONIC HEPATITIS B INFECTION , 1988, The Lancet.

[10]  M. Peters,et al.  Prednisone withdrawal followed by recombinant alpha interferon in the treatment of chronic type B hepatitis. A randomized, controlled trial. , 1988, Annals of internal medicine.

[11]  R. Beasley Hepatitis B virus. The major etiology of hepatocellular carcinoma , 1988, Cancer.

[12]  Ching-lung Lai,et al.  PLACEBO-CONTROLLED TRIAL OF RECOMBINANT α2-INTERFERON IN CHINESE HBsAg-CARRIER CHILDREN , 1987, The Lancet.

[13]  A. Lok,et al.  Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. , 1987, Gastroenterology.

[14]  A. Lok,et al.  Placebo-controlled trial of recombinant alpha 2-interferon in Chinese HBsAg-carrier children. , 1987, Lancet.

[15]  O. Yokosuka,et al.  Recombinant leukocyte a interferon treatment in patients with chronic hepatitis B virus infection. Pharmacokinetics, tolerance, and biologic effects. , 1985, Gastroenterology.

[16]  T. Merigan,et al.  Antiviral treatment of chronic hepatitis B virus infection. I. Changes in viral markers with interferon combined with adenine arabinoside. , 1981, The Journal of infectious diseases.